We identified the overexpression of ANRIL in 13 among the 17 cancer types compared to normal tissues. Interestingly, the expression status of ANRIL was different depending on histological subtype, tumor stage, and tumor grade. This evidence concerns the gene CDKN2B-AS1 and cancer.